India plans to increase pharmaceutical exports to Russia, the Netherlands and Brazil, aiming to expand its presence beyond the United States, its largest market, amid tariff-related concerns. India’s pharmaceutical industry is currently exempt from US President Donald Trump’s tariffs of up to 50% but the sector has been on edge due to the uncertainty surrounding the situation. The US accounts for slightly more than a third of India’s pharmaceutical exports, primarily comprising cheaper generic versions of popular drugs. Sales in the country rose 20% to approximately $10.5 billion in fiscal 2025. The idea is to diversify the export chain and increase market share in other countries. The United Kingdom is India’s second-largest export market, with $914 million in sales, followed by Brazil with $778 million. Exports to the Netherlands and Russia stood at $616 million and $577 million, respectively, in fiscal 2025, according to government data, as per a report.